title: Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy.
abstract: Nucleoside analogs are a significant class of anti-cancer agent. As prodrugs, they terminate the DNA synthesis upon transforming to their active triphosphate metabolites. We have encapsulated a biologically activate nucleotide analog (i.e. gemcitabine triphosphate (GTP)), instead of the nucleoside (i.e. gemcitabine) derivative, into a novel Lipid/Calcium/Phosphate nanoparticle (LCP) platform. The therapeutic efficacy of LCP-formulated GTP was evaluated in a panel of human non-small-cell lung cancer (NSCLC) and human pancreatic cancer models after systemic administrations. GTP-loaded LCPs induced cell death and arrested the cell cycle in the S phase. In vivo efficacy studies showed that intravenously injected GTP-loaded LCPs triggered effective apoptosis of tumor cells, significant reduction of tumor cell proliferation and cell cycle progression, leading to dramatic inhibition of tumor growth, with little in vivo toxicity. Broadly speaking, the current study offers preclinical proof-of-principle that many active nucleotide or phosphorylated nucleoside analogs could be encapsulated in the LCP nanoplatform and delivered systemically for a wide variety of therapeutic applications.
authors: Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7571, USA.
authors: Yuan
authors: Y
authors: Zhang
authors: William Y
authors: WY
authors: Kim
authors: Leaf
authors: L
authors: Huang
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D002118:Calcium / Q000737:chemistry; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D020169:Caspases / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D003570:Cytidine Triphosphate / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D004789:Enzyme Activation / Q000187:drug effects; D005260:Female; D006801:Humans; D008055:Lipids / Q000737:chemistry; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D051379:Mice; D008819:Mice, Nude; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D010316:Particle Size; D010710:Phosphates / Q000737:chemistry; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism; D011092:Polyethylene Glycols / Q000737:chemistry; D016196:S Phase / Q000187:drug effects; D055672:Static Electricity; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D008055:Lipids; D010710:Phosphates; D011092:Polyethylene Glycols; D003570:Cytidine Triphosphate; C533693:gemcitabine triphosphate; D011065:Poly(ADP-ribose) Polymerases; D020169:Caspases; D002118:Calcium
references: Anticancer Res. 2007 Jan-Feb;27(1A):195-9
references: 17352232
references: Biochemistry. 1996 May 7;35(18):5616-23
references: 8639519
references: J Control Release. 2012 Feb 28;158(1):108-14
references: 22056915
references: Antiviral Res. 2006 Sep;71(2-3):282-92
references: 16735066
references: Pharm Res. 2011 May;28(5):1167-78
references: 21340573
references: Appl Environ Microbiol. 1980 Sep;40(3):549-61
references: 16345634
references: Nucleic Acids Res. 2012 Mar;40(5):1891-903
references: 22075995
references: J Control Release. 2009 Nov 16;140(1):55-60
references: 19616596
references: Chem Rev. 2009 Jul;109(7):2880-93
references: 19476376
references: Cancer Res. 2001 Dec 15;61(24):8723-9
references: 11751391
references: Int J Pharm. 2012 Jun 15;429(1-2):123-34
references: 22425885
references: Clin Pharmacokinet. 2000 Jul;39(1):5-26
references: 10926348
references: Anticancer Res. 1997 May-Jun;17(3B):1577-82
references: 9179197
references: Oncologist. 1997;2(3):127-134
references: 10388042
references: Cancer Lett. 2012 Jul 28;320(2):138-49
references: 22425961
references: Biochem J. 1997 Aug 15;326 ( Pt 1):1-16
references: 9337844
references: Bioorg Med Chem Lett. 2008 May 1;18(9):2957-8
references: 18396042
references: Bioorg Med Chem. 2012 May 15;20(10):3323-31
references: 22512908
references: Eur J Pharm Sci. 2010 Nov 20;41(3-4):498-507
references: 20728535
references: J Control Release. 2004 Dec 10;100(3):331-46
references: 15567500
references: Biochim Biophys Acta. 2009 Oct;1788(10):2259-66
references: 19595666
references: Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
references: 2946403
references: Nanomedicine. 2011 Dec;7(6):859-70
references: 21550422
references: Methods Mol Med. 2001;52:213-8
references: 21340945
references: PLoS One. 2012;7(2):e31067
references: 22348037
references: J Clin Invest. 1987 Feb;79(2):380-7
references: 3805274
references: Nanomedicine. 2011 Dec;7(6):841-9
references: 21419876
references: Bioconjug Chem. 2011 Oct 19;22(10):1983-93
references: 21863885
references: Mol Ther. 2012 Jul;20(7):1298-304
references: 22525514
references: Int J Cancer. 2004 Nov 20;112(4):693-700
references: 15382053
references: Int J Pharm. 2011 Mar 15;406(1-2):69-77
references: 21219999
references: J Control Release. 2010 Mar 19;142(3):416-21
references: 19919845
references: Surgery. 2012 Sep;152(3 Suppl 1):S152-6
references: 22763259